A n impaired ability to excrete Na + load is commonly seen in patients with chronic heart failure (CHF). 1,2 CHF and chronic kidney disease often coexist. 3,4 This coexistence of CHF and chronic kidney disease is commonly referred to the cardiorenal syndrome. However, elucidating the contribution of specific molecular mechanism/s for the inappropriate Na + and water retention commonly seen in CHF remains largely undefined.
camostat mesilate, an orally active synthetic serine protease inhibitor, has been shown to reduce blood pressure and renal injury in salt-sensitive hypertension. 18 The protease mechanism related to ANG II-aldosterone axis has also been shown to stimulate ENaC activity in the renal tubule. 19, 20 Thus, we hypothesized that tubular proteases contribute to the activating ENaC in rats with CHF. In the present study, we attempted to address the following questions: (1) are the levels of proteases increased in the urine of rats with CHF and patients with CHF? (2) do urinary proteases increase ENaC activity of renal tubules and Na + retention in rats with CHF? (3) is there increased podocyte injury which would result in increased leakage of proteases into renal tubular fluid in rats with CHF?
Methods

Study Approval
All the procedures on animals in this study were approved by the University of Nebraska Medical Center Institutional Animal Care and Use Committee. The experiments were conducted according to the American Physiological Society Guiding Principles for Research Involving Animals and Human Beings and the National Institues of Health guide for the care and use of laboratory animals.
The human study was approved by the local institutional review committee (Ethik-Kommission) of the Martin-Luther University Halle-Wittenberg (Study number 2011-64). All subjects gave informed consent before study participation.
Statistics
Data were subjected to a 2-way ANOVA followed by a Multiple Range (for multiple comparisons) or Student Newman-Keuls test. P<0.05 was considered to indicate statistical significance.
Detailed description of procedures is available in Methods in the online-only Data Supplement.
Results
Basal Hemodynamic Characteristics
The myocardial infarct model in the rat mimics the most common cause of CHF in humans and is used in numerous laboratories. 11, [21] [22] [23] [24] Table 1 summarizes the salient characteristics of sham and CHF rats used in the present study. Heart weight, body weight, and wet lung weight were significantly higher in CHF rats compared with sham rats (P<0.05). The CHF group displayed an average myocardial infarct of >30% of the left ventricle. In contrast, sham rats had no observable damage to the myocardium. Left ventricular end-diastolic pressure was significantly elevated in CHF rats compared with sham rats (P<0.05). +dP/dt max was significantly decreased in CHF rats, indicating decreased contractility of the left ventricles. This contractile dysfunction was likely the cause for the increase in left ventricular end-diastolic pressure. −dP/dt max had a similar trend in rats with CHF. These data suggest that rats in the CHF group had decreased cardiac contractility and were experiencing diastolic dysfunction. Overall, these characteristics indicate that CHF rats were in heart failure and possibly retaining fluid. Table 2 summarizes the renal and hemodynamic characteristics of patients with CHF and control subjects recruited in the present study. Patients with CHF (New York Heart Association III-IV) had significantly increased levels of plasma brain natriuretic peptide and creatinine compared with the control subjects without CHF. Further, left ventricular ejection fraction was significantly decreased (32±6% versus 68±1%, P<0.05) in the patients with CHF compared with the control subjects.
Urinary Serine Proteases Were Increased in CHF
We examined several urinary serine proteases in sham and CHF rats ( Figure 1A ). Four weeks after coronary ligation or sham surgery, 24 hours urine samples were collected from metabolic cages and processed for protease measurement by immunoblotting. We found that several urinary serine proteases were significantly increased in CHF compared with the sham rats (fold increases: furin 6.7, prostasin 23.6, plasminogen 2.06, and plasmin 3.57 versus sham, P<0.05). Urinary protease activity measured using zymogram also demonstrated increases in CHF rats (≈5-folds versus sham; Figure 1B ). Similarly, we found that these 3 proteases in the urine were also increased in the patients with CHF (fold increases: furin 7.0, prostasin 7.7, plasminogen 5.4, and plasmin 3.9 versus control, P<0.05; Figure 2 ). This is the first evidence showing increased urinary serine proteases in the CHF condition to our knowledge.
Protease-Rich Urine Activated ENaC in Cultured Renal Cortical Collecting Duct M-1 Cells
Because we found significantly increased urinary proteases in rats with CHF, this study was designed to investigate the functional effects of protease-rich urine (from rats and patients with CHF) on ENaC activity in cultured renal CCD M-1 cells. M-1 mouse CCD cell line (purchased from ATCC) was established from normal renal tissue. These cells retain many characteristics of CCD cells, including the morphology and CCD antigens. Whole-cell patch clamp was conducted on these M-1 cells to record Na + currents before and after exposure to the urine (collected from sham and CHF rat, or control and CHF patient). The results show that protease-rich urine, from rats or patients with CHF, increases the Na + inward current in M-1 cells compared with the sham rats or control patients urine exposure, respectively ( Figure 3A and 3C). The stimulatory effect of urine on the Na + inward current was reduced by ENaC inhibitor amiloride and pretreatment with protease inhibitor aprotinin in the urine ( Figure 3A and 3B ). On the contrary, the urine collected from sham rats or control patients did not increase the ENaC activity in M-1 cells. Addition of aprotinin to the urine collected from sham rats did not affect the inward Na + current. This study supports the notion that proteases in the renal tubule have a potentially important role in activating ENaC of renal tubular cells in rats with CHF.
Diuretic and Natriuretic Responses to ENaC Inhibitor
After 2 weeks of protease inhibitor, aprotinin treatment, there were no significant differences in kidney weights between the groups of rats with or without aprotinin ( Table 3 ). The basal urine flow before benzamil injection was not significantly different between the 2 sham groups. The basal Na + excretion before benzamil injection was significantly increased in CHF group with aprotinin treatment. Benzamil injection produced diuresis and natriuresis in both groups of rats ( Figure 4 ). Both diuresis and the natriuresis responses were significantly increased in CHF group compared with the corresponding sham rats after benzamil injection (P<0.05), consistent with our previous observations. 11 Aprotinin significantly reduced the diuretic and natriuretic responses to benzamil in CHF ( Figure 4A and 4B). Aprotinin did not significantly change the diuretic and natriuretic responses to benzamil in the sham group. This study provides additional evidence to support the idea that proteases in the renal tubule have an important role to activate ENaC. Further, protease inhibitors may reduce Na + retention in CHF by attenuation of ENaC activity in the kidney.
In the patch clamp study, protease-rich urine from rats with CHF increased the Na + inward current in M-1 cells compared with the sham urine exposure as shown above. However, the stimulatory effect of urine on the Na + inward current was reduced by the urine from CHF rats with aprotinin treatment ( Figure 4C ), suggesting that long-term protease treatment is effective in preventing the enhanced activation of ENaC observed in CHF.
Podocyte Integrity; Desmin and Podocin Expression in Rats With CHF
Podocyte lesions were found in the kidneys of rats with CHF. The number of podocytes and foot process width were detected by transmission electron microscopy (n=3; Figure 5A ). Generally, there was a fairly large amount of damage in the kidneys of rats with CHF compared with sham rats. In particular, podocyte foot processes lost their normal shape and displayed numerous areas of effacement. The glomerular basement membrane also displayed abnormal thickness in rats with CHF. Further, we found that desmin immunosignal, a marker for podocyte injury, 25 was enhanced in podocytes of CHF rats demonstrated by immunostaining (n = 6; Figure 5B ). Finally, both desmin and podocin protein expressions (another podocyte damage marker) were significantly increased in the cortex of rats with CHF (P<0.05; Figure 5C and 5D).
Discussion
The present study shows that several urinary serine proteases are significantly increased in patients, as well as in rats, with CHF. This protease-rich urine (from rats with CHF versus Sham-operated rats) significantly increased Na + inward current in M-1 cells. Conversely, treatment with a protease inhibitor for 2 weeks significantly abrogated the enhanced diuretic and natriuretic responses to ENaC inhibitor, benzamil, in rats with CHF. At this phase of the disease, we observed that there was dramatic damage to the podocytes in the kidneys from rats with CHF. Taken together, these data suggest a robust increase in ENaC activation because of tubular proteases, possibly owing to podocyte damage, which leads to the enhanced Na + reabsorption in CHF. Na + and fluid retention are commonly seen in patients with CHF. Recently, the role of proteases in activating ENaC has been highlighted in several reviews. 26, 27 However, there is not much evidence for this in a disease state, such as CHF, the focus of the current study. ENaC can be stimulated by soluble proteases, such as trypsin, membrane-bound proteases, such as plasmin and prostasin, and intracellular protease furin. Proteases have important roles in activation of ENaC by cleaving parts of αand γsubunits and releasing intrinsic inhibitory tracts. 27 Activation of ENaC may contribute to the Na + retention and tissue congestion commonly observed in disease conditions, such as CHF. In the present study, we found that several proteases prostasin, plasmin, and furin were dramatically increased in the urine from both patients with CHF and rats with CHF. This is the first evidence showing increased urinary serine proteases in the CHF condition, to our knowledge.
To test the potency of these proteases to activate the ENaC in vitro, we used patch clamp measurement of Na + current in cultured tubular M-1 cells exposed to urine collected from rats or patients with CHF and controls. The results demonstrate that urine collected from CHF rats or patients yield greater inward Na + current compared with urine from controls. The increased inward Na + current in CHF was normalized by protease inhibitor treatment. Our in vivo and in vitro studies provided complimentary evidence showing a direct effect of enhanced proteases on the ENaC activity and Na + dysregulation in rats with CHF. All these results support the idea that increased proteases in tubular fluid increase ENaC activity and Na + retention in rats with CHF.
The M-1 cell line is derived from microdissected CCD of transgenic mouse and displays the low conductance, highly Na + -selective channel activity of the α-, β-, and γ-ENaC subunits. It retains many antigenic and differentiated transport properties of the CCD. It has been used extensively to study amiloride-sensitive Na + transport through ENaC. 17, 28, 29 In our patch clamp study, the amiloride-sensitive, protease-activated inward Na + current identified here in M-1 cells is consistent with ENaC as the target but not definitive. The contribution from other amiloride-sensitive Na + conducting channels, such as ENaC-like channels and a nonselective cation channels in M-1 cells, cannot be conclusively excluded by these particular experiments.
Our previous work has shown increased ENaC subunit abundance and enhanced ENaC functional activity in rats with CHF. 11 This may also contribute to the Na + retention observed in CHF. Interestingly, as mentioned above, our data show that urinary serine proteases (furin, prostasin, plasminogen, and plasmin) are all dramatically increased in CHF. Aprotinin, a broad-spectrum serine protease inhibitor, has displayed inhibitory effects on Na + channel activity in the kidney. 30, 31 Based on these studies, we examined the contribution of proteases causing increased ENaC activity and Na + retention in rats with CHF. In vitro studies demonstrated that addition of aprotinin to the urine of rats with CHF was able to abrogate the enhanced activation of ENaC, suggesting that excess proteases in the urine of CHF rats were responsible for the enhanced functionality of the ENaC in the CHF condition. Further, our results showed that in rats with CHF, treatment with aprotinin to block endogenous proteases for 2 weeks abrogated the enhanced ENaC activity responses to benzamil (increase urine volume and Na + excretion). These results demonstrate that there is an enhanced functional activation of ENaC, which is dependent on tubular proteases in rats with CHF.
Aprotinin is an important member of a family of related protease inhibitors and has many clinically beneficial activities. 32 In the clinic, aprotinin has been widely used as pre-and intraoperative agents with antifibrinolytic activity. 33 It also has complex interactions with other drug therapies, including ANG-converting enzyme inhibitors. 32 It may also affect hemodynamics in this regard. Our in vivo and in vitro studies provide evidence showing the direct effect of protease on the ENaC activity and Na + dysregulation in CHF rats. A potential concern for this protocol is the efficacy of the protease inhibitors on renal ENaC activity. As a potential protease inhibitor, aprotinin has been shown to prolong the attenuation of ENaC function in the lung, airway, and kidney. 28, 34, 35 Aprotinin has higher potency than other protease inhibitors, such as soybean trypsin inhibitors, to attenuate ENaC function and Na + retention.
Furin is an intracellular convertase-type protease that resides primarily in the trans-Golgi network. Urinary furin is more likely from epithelial cells of the kidney rather than from circulation or glomerular podocyte leakage. The source of urinary furin may be different from extracellular proteases plasmin and prostasin. Aprotinin can block the activity of proteases, such as prostasin and plasmin 36 ; however, it has been reported that aprotinin at a dose of 0.1 mg/mL does not block furin. 37 Administration of the synthetic serine protease inhibitor camostat mesilate inhibits the protease activity of serine proteases, such as prostasin and plasmin, but not furin. This protease inhibitor may inhibit the second cleavage of γ-ENaC and subsequently suppress ENaC activity on the plasma membrane. 38 The sympathetic nervous system and the renin-ANG IIaldosterone system have been suggested as possible cardiorenal mediators. 39 In CHF patients and rats with CHF, increased sympathetic nerve activity has been well documented. 40, 41 The plasma levels of norepinephrine, ANG II, and aldosterone are all elevated in patients with CHF, as well in rats with CHF. [42] [43] [44] ANG II and aldosterone are well recognized for their actions on ENaC in increasing Na + reabsorption. [7] [8] [9] Interventional 10 Beyond this well-known action, a recent study suggests an additional mechanism by which ANG II and aldosterone could stimulate Na + transport through ENaC by increasing the expression of proteases in the kidney. 45 Activated norepinephrine and ANG II-aldosterone systems are involved in several renal injury processes, including glomerular podocyte injury. 10, 46 Aldosterone is implicated in renal inflammatory and fibrotic processes, as well as in podocyte injury and mesangial cell proliferation. 10 Activation of the sympathetic nervous system augments kidney renin-ANG system and oxidative stress. Intrarenal ANG II-induced increases in reactive oxygen species may contribute to the pathogenesis of glomerular podocyte injury and albuminuria. 46 Severe proteinuria and renal injury are also found in patients with CHF. 47, 48 The defective glomerular filtration barrier allows the filtration of ENaC-activating proteases, such as plasmin converted from plasminogen into the tubular fluid. In our study, we found that podocyte foot processes lost their normal shape and displayed numerous areas of effacement in CHF rats. We also found that desmin and podocin protein expression, as markers for podocyte injury, were enhanced in the podocytes of kidneys from rats with CHF. Thus, we propose that in CHF, there is an increased damage to the podocytes that leads to leakage of proteases from the glomerulus into the tubular fluid which in turn causes an enhanced activation of ENaC, leading to enhanced Na + retention ( Figure 6 ).
Cardio-renal syndrome describes the reciprocally detrimental interaction between chronic cardiac and renal dysfunction. The syndrome is highly prevalent and carries a high risk of mortality. The main therapy of cardio-renal syndrome is loop diuretics and ANG-converting enzyme inhibition. One emergent feature of this study is that CHF presents itself as exhibiting enhanced levels of urinary proteases, and perhaps, they represent urinary biomarkers of renal injury in patients with CHF. These data lead us to speculate that urinary proteases may perhaps be used as a biomarker of cardio-renal disease. Further studies need to evaluate a therapeutic and preventive strategy to delay the onset and progression of CHF and cardio-renal syndrome by using protease inhibitor administration.
In conclusion, these findings demonstrate that increased proteases in the tubular fluid contribute to the enhanced ENaC activity and, thus, Na + retention commonly seen in patients with CHF. The significance of these studies is to provide insight into the molecular and cellular mechanisms that may contribute to activation of ENaC and, consequently, lead to dysfunction in Na + balance, commonly observed in CHF. 
Perspectives
The significance of these studies is to provide insight into the molecular and cellular mechanisms that contribute to ENaC activation associated with dysfunction in sodium balance in CHF. Additionally, the present studies provide novel information on the beneficial effects of protease inhibition on renal sodium regulation in CHF, which may allow us to develop new treatments and management programs for the complications and consequences of CHF. This is the first study that determines the role of proteases in affecting the activity of ENaC and its contribution to sodium balance dysfunction in CHF. These studies also examine the underlying possible mechanisms of enhanced protease activation of ENaC in CHF. The amalgamation of the observations in this fashion also represents a novel and an innovative approach to the study of renal handling of sodium and water in CHF. 
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